Intervention

Autologous Tumor Infiltrating Lymphocytes LN-145-S1

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 1 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials1

Recruiting0

Common conditions16

Lead sponsors shown1

Clinical trials

1 shown

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasNCT03449108 · 2018-04-27

ACTIVE_NOT_RECRUITING

Common conditions

Bone Sarcoma1 Dedifferentiated Chondrosarcoma1 Giant Cell Tumor of Bone1 Malignancy in Giant Cell Tumor of Bone1 Malignant Solid Neoplasm1 Ovarian Carcinosarcoma1 Platinum-Resistant Ovarian Carcinoma1 Poorly Differentiated Thyroid Gland Carcinoma1 Recurrent Osteosarcoma1 Recurrent Ovarian Carcinoma1 Refractory Osteosarcoma1 Soft Tissue Sarcoma1 Thyroid Gland Anaplastic Carcinoma1 Thyroid Gland Squamous Cell Carcinoma1 Triple Negative Breast Cancer1 Undifferentiated High Grade Pleomorphic Sarcoma of Bone1

Leading sponsors

M.D. Anderson Cancer Center 1

Trial status mix

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.